- Home
- CLSD
CLSD
Clearside Biomedical Inc.
as 03-28-2025 4:00pm EST
| Founded: | 2011 | Country: | United States |
| Employees: | N/A | City: | ALPHARETTA |
| Market Cap: | N/A | IPO Year: | 2016 |
| Target Price: | $5.20 | AVG Volume (30 days): | 220.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.47 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.77 - $1.65 | Next Earning Date: | 03-27-2025 |
| Revenue: | $1,664,000 | Revenue Growth: | -79.77% |
| Revenue Growth (this year): | 82.99% | Revenue Growth (next year): | 274.78% |
Stock Insider Trading Activity of Clearside Biomedical Inc. (CLSD)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Thorp Clay | CLSD | Director | Feb 24 '25 | Buy | $0.92 | 15,000 | $13,800.00 | 176,141 |
Latest Clearside Biomedical Inc. News
CLSD Breaking Stock News: Dive into CLSD Ticker-Specific Updates for Smart Investing
Simply Wall St.
2 days ago
Clearside Biomedical Full Year 2024 Earnings: In Line With Expectations
Zacks
3 days ago
Clearside Biomedical, Inc. (CLSD) Reports Q4 Loss, Tops Revenue Estimates
GlobeNewswire
3 days ago
Clearside Biomedical Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
GlobeNewswire
7 days ago
Clearside Biomedical Announces Six Abstracts Accepted for Presentation at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting
GlobeNewswire
11 days ago
Clearside Biomedical’s Lead Clinical Program CLS-AX in Wet AMD and Suprachoroidal Delivery Platform Highlighted at the 2025 Wet AMD & Diabetic Eye Disease Summit
GlobeNewswire
19 days ago
Clearside Biomedical to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update on Thursday, March 27, 2025
GlobeNewswire
25 days ago
Clearside Biomedical Announces Successful End-of-Phase 2 Meeting with the FDA and Alignment on Phase 3 Plans for Suprachoroidal CLS-AX in Wet AMD
Zacks
a month ago
Zai Lab Limited (ZLAB) Surges 9.0%: Is This an Indication of Further Gains?
Compare CLSD vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CLSD Clearside Biomedical Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.